Professional Media Briefs

Share this article:
Brandofino Communications partnered with Augme Mobile to create Augme Mobile Health, a mobile service offering pharma brands a platform to deliver content direct to mobile phones. Consumers can request coupon offers, brochures and other information by text message.

Slack Incorporated promoted Mike Graziani to VP, sales. Graziani was previously senior director of sales and marketing for Slack's specialty medicine division. In his new role, Graziani will manage sales teams for the specialty medicine, surgery & related sciences, association services and classified sales divisions.

CMPMedia's title Diagnostic Imaging Europe introduced a new magazine layout and expanded its editorial board to include six new international advisors: Filipe Caseiro, of Portugal; Katarzyna Gruszczynska, of Poland; Andrea Klauser, of Austria; Philippe Lefere, of Belgium; Anne Paterson, of the UK; and Anders Persson, of Sweden.

The New England Journal of Medicine launched a Facebook page, joining other professional publications in the medium. The NEJM's Facebook page offers recent and popular articles, and a weekly podcast summary.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?